Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00228-007-0318-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Distinctive Optical Coherence Tomography Angiography and Indocyanine Green Angiography Imaging Patterns in Topiramate-Induced Choroidal Effusion.
Retin Cases Brief Rep
December 2023
Vitreous Retina Macula Consultants of New York, New York, NY.
Purpose: To describe novel findings seen on optical coherence tomography angiography (OCTA) and indocyanine green angiography (ICGA) in a young male patient presenting with bilateral topiramate-induced choroidal effusion.
Methods: Retrospective case report. A comprehensive ophthalmic examination was conducted and multimodal imaging techniques, including B-scan ultrasound, OCT, OCTA, and ICGA were analyzed.
Combination of venlafaxine and phentermine/topiramate induced psychosis: A case report.
Ment Health Clin
March 2018
Psychiatric Pharmacist and Residency Director, Captain James A. Lovell Federal Health Care Center, North Chicago, Illinois.
Background: Various publications have noted increases in dopamine, specifically in the mesolimbic region of the brain, to have a direct correlation to psychotic-like symptoms. Venlafaxine, a first-line medication for depression, inhibits the reuptake of both serotonin and norepinephrine. Additionally, venlafaxine weakly inhibits the reuptake of dopamine.
View Article and Find Full Text PDFTopiramate-induced weight loss depends on level of intellectual disability in patients with epilepsy.
Epilepsy Behav
June 2018
North Tohoku Epilepsy Center, Minato Hospital, Hachinohe, Aomori, Japan.
Objective: Intellectual disability (ID) is associated with weight gain caused by antiepileptic drugs such as valproic acid. The present study analyzed the relationship between ID and weight loss caused by topiramate (TPM).
Methods: Seventy-eight patients with epilepsy (35 women, aged 18 to 70years) were enrolled in this prospective study.
Hallucinations Associated with Topiramate Therapy: A Case Report and Review of the Literature.
Curr Drug Saf
June 2018
Department of Psychiatry and Behavioral Neurosciences, Women's Center Psychiatrist; Ambulatory Care Service, James A. Haley Veterans Hospital, University of South Florida, Morsani College of Medicine, Tampa, FL. United States.
Background: Topiramate is a medication that is approved as both monotherapy and adjunctive treatment of seizure disorder in adults and adolescents. It is also approved for migraine prophylaxis. It has been associated with many side effects, including weight loss and the development of renal stones.
View Article and Find Full Text PDFA candidate-gene association study of topiramate-induced weight loss in obese patients with and without type 2 diabetes mellitus.
Pharmacogenet Genomics
February 2016
aNeuroscience Therapeutic Area, Janssen Research & Development, LLC, Titusville, New Jersey bCVM Therapeutic Area, Janssen Research & Development, LLC, Spring House, Pennsylvania cPerlegen Sciences, Mountain View, California dAthanasiou Consulting, LLC, Fond du Lac, Wisconsin, USA.
Objective: Clinical response to topiramate can vary greatly in obese patients. Identifying genetic variants associated with treatment response could help gain insight into the mechanism of action of topiramate. Little is known about the relationship between genetic variability and topiramate treatment response.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!